RxDoctor Payments DataLook up a doctor →

Ernest Hendrix, MD

Family Medicine · Athens, ALNPI 1831182567

Payments from drug & device makers

$2,440,182in general payments, 2019–2025

Across 269 payments — averaging $9071.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.8M
  • Novartis$481K
  • AbbVie$82K
  • AstraZeneca$46K
  • Amgen$16K
  • GSK$7K
  • plus $6K from 9 others

What the payments were for

  • Food & beverage$59997%
  • Gifts$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer152$1,801,851
Novartis7$480,700
AbbVie(2 entities)77$82,453
AstraZeneca7$46,289
Amgen3$15,975
GSK2$6,500
Merck2$6,000
Indivior Inc.6$150
Novo Nordisk3$66
Abbott3$63
Exact Sciences2$41
Otsuka America Pharmaceutical, Inc.2$39
Antares Pharma, Inc.1$29
Lilly USA, LLC1$14
Daiichi Sankyo Inc.1$12

How this compares

$2,440,182 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$84,713
Medicare patients
180
Services billed
1,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol147$99,457
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl373$61,106
EliquisApixaban67$41,257
LinzessLinaclotide55$34,623
OzempicSemaglutide23$30,487
JardianceEmpagliflozin29$25,062
JanuviaSitagliptin Phosphate29$21,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,179
ZubsolvBuprenorphine Hcl/Naloxone Hcl31$17,873
TrulicityDulaglutide13$17,786
Breo ElliptaFluticasone/Vilanterol28$12,451
MounjaroTirzepatide11$11,348
Buprenorphine Hcl182$10,918
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$7,052
SymbicortBudesonide/Formoterol Fumarate24$6,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$46,289$105,961171 claims
PfizerEliquis$1,801,851$41,25767 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$6,500$36,28171 claims
AbbVieLinzess$82,453$34,62355 claims
Novo NordiskOzempic$66$30,48723 claims
Lilly USA, LLCTrulicity, Mounjaro$14$29,13424 claims
MerckJanuvia$6,000$21,74429 claims
Indivior Inc.Suboxone$150$7,05214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →